I reached out to Australian brand Vital+ and got my hands on their Ice Bath Pro tub and the Ultra X1 Chiller. My goal was to set up an at-home ice bath that’s easy to use regularly, portable ...

Water Cooled Chiller for Air Conditioning Cooling (LTLS Series 100-2000KW) Model Details: LT L S---30 W (R) S (D) LT--LVTE Company Products Code L--Screw Compressors S--Chiller, Cooling Only ...

VKTX's Ongoing Development Activities Related to VK2735 The VANQUISH clinical program is supported by data from the phase II VENTURE study, which evaluated once-weekly VK2735 SC for 13 weeks. The ...

RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR ...

A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but demonstrated fast-acting healing of the ocular surface, according to a ...

News Channel 3-12 is committed to providing a forum for civil and constructive conversation. Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here ...

In potential good news for Prothena, Roche announced earlier this week that it will advance Prothena-partnered prasinezumab into phase 3 trials for early-stage Parkinson’s disease, despite the ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Bitcoin is just starting to accelerate higher again ...

EFZO-CONNECT™ is a Phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with limited or ...

Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance ...

It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness.